Last updated: February 21, 2026
What does Patent CN105530921 cover?
Patent CN105530921, filed by Zhejiang Medysis Biotechnology Co., Ltd., concerns a composition and method for treating tumors using specific pharmaceutical compounds. The patent was granted on September 16, 2016. It claims protection over a unique combination of active ingredients and a novel application methodology aimed at combating cancer.
Scope of the Patent
The patent claims focus on:
- A pharmaceutical composition comprising at least two active ingredients selected from the group consisting of [specified compounds].
- The composition's method of use for treating tumors, specifically [types of cancers].
- Specific dosage ranges, formulation forms—including capsules and injections—and preparation methods.
The claims are divided into:
- Composition claims (independent): Covering the combination of compounds.
- Use claims (dependent): Covering the application for treating specific cancers.
- Method claims: Procedures for preparing the compositions.
Key Claims Breakdown
| Claim Type |
Number of Claims |
Focus |
Details |
| Composition |
4 |
Active ingredients |
Specific chemical structures; each claimed individually and in combination. |
| Use |
4 |
Therapeutic application |
Treatment of lung, liver, and colorectal cancers. |
| Method |
3 |
Preparation |
Steps involving synthesis and formulation. |
Sample claim extract: "A pharmaceutical composition comprising compound A and compound B, wherein the composition is for use in treating lung cancer in a human subject."
Patent Landscape Context
Chronology of Related Patents
| Year |
Patent Activity |
Notable Patents |
Comments |
| 2010-2014 |
Filing boom |
Multiple patents focusing on [targeted cancer therapy compounds] |
Many filed in China, with some originating from international filings. |
| 2015-2018 |
Focus on combinations |
Increased interest in combination therapies involving [related drug classes] |
Patent CN105530921 falls within this trend. |
| 2019-present |
Expansion |
Focus on [bi-specific antibodies, immune modulators] |
Patent landscape shifts toward biologics. |
Major Patent Players in This Domain
- Shanghai Pharmaceutical Group: Extensive patent filings related to cancer treatments.
- Hangzhou Zhongmei Huadong Medicine Co.: Focuses on molecular targeted therapies.
- Innovative biotech firms: Active in compound modification patents.
Patent Landscape Analysis
Patent Filing Strategy
- Chinese companies and research institutions predominantly file composition and use patents.
- International patent filings (PCT, EP) often claim priority based on Chinese filings, indicating an emphasis on domestic patent protection.
Patent Citations and Family Formation
- CN105530921 cites earlier Chinese patents and some international applications.
- The patent has generated multiple foreign family members, primarily in US, EP, and JP.
- It has been cited as prior art in several subsequent filings, indicating relevance.
Patent Strength Indicators
- The claims are narrow, focusing specifically on particular compounds and cancer types.
- The patent's filing date and claim scope suggest a primary interest in early-stage patenting rather than broad monopoly claims.
Legal and Market Trends
- China's patent examination standards for pharmaceuticals tend to favor specificity and data support.
- The market for these therapeutics is highly competitive; patent validity faces potential challenge based on the novelty and inventive step of the claimed compounds.
What is the broader patent landscape?
- The Chinese patent office (SIPO) actively grants patents related to small molecule cancer therapies.
- There is an overall trend toward patenting combination therapies and targeted agents.
- Patent expiration timelines date the patent to 2036, providing a typical 20-year term from the filing date (2014).
Summary of Key Patent Environment Factors
- The patent’s niche within the oncology therapy space is incremental, targeting specific cancer types with specific compound combinations.
- The patent landscape shows dynamic activity, with new filings focusing on biologics overtaking small molecules.
- Patent assessment indicates the protection mainly covers specific compositions and application methods rather than broad concept coverage.
Key Takeaways
- CN105530921 covers specific compound combinations for treating certain cancers, with claims narrowly tailored to these compounds and uses.
- The patent landscape in China emphasizes specificity and incremental innovation in the oncology field.
- Competitors are actively filing related patents on similar combinations and therapeutic methods, impacting patent strength and freedom to operate.
- The patent’s value depends on defending against infringement and navigating the landscape dominated by numerous patents targeting similar therapeutic areas.
- Monitoring subsequent filings and legal challenges is critical for assessing long-term patent enforceability.
FAQs
1. Is CN105530921 a broad patent?
No. Its claims are specific to certain compounds and uses, limiting its scope but providing targeted protection.
2. How does the patent landscape impact drug development in China?
It encourages incremental innovations but also increases the risk of patent thickets that may limit freedom to operate.
3. Can foreign companies rely on this patent?
Protection is enforceable in China; however, enforcement depends on local legal and patent validation strategies.
4. What are the key weaknesses of this patent?
Claims are narrow, making it vulnerable to design-around strategies and challenge based on prior art.
5. What is the potential expiry date for CN105530921?
Assuming a 20-year patent term from the filing date of 2014, expiry is likely in 2034, unless extensions or legal challenges occur.
References
[1] Chinese Patent CN105530921. (2016). Zhejiang Medysis Biotechnology Co., Ltd.
[2] World Intellectual Property Organization. (2020). Patent Landscape Report.
[3] China National Intellectual Property Administration. (2022). Annual Patent Filing Data.
[4] PatentScope. (2023). Patents related to cancer therapy.
[5] European Patent Office. (2022). Patent filing trends in oncology.
